Skip to main content
SpringerLink
Log in

Effects of thiazolidinediones on cardiovascular risk factors

  • Original Article
  • Published:
Comprehensive Therapy

Abstract

The thiazolidinediones are the insulin sensitizers used in the management of Type 2 diabetes mellitus. These drugs can potentially decrease the risk of cardiovascular disease by correcting the different components of the insulin resistance syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fonseca V. Rosenstock J. Patwardhan R. Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA. 2000;283:1695–1702.

    Article  PubMed  CAS  Google Scholar 

  2. Miyazaki Y, Mahankal, A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24:710–719.

    Article  PubMed  CAS  Google Scholar 

  3. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. The Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metabol. 2001;86:280–288.

    Article  CAS  Google Scholar 

  4. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. The Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24:308–315.

    Article  PubMed  CAS  Google Scholar 

  5. Auwerx J. PPARgamma: The ultimate thrifty gene. Diabetologia. 1999;42:1033–1049.

    Article  PubMed  CAS  Google Scholar 

  6. Santomauro AT, Boden G, Silva ME, et al. Overnight lowering of FFAs with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes. 1999;48:1836–1841.

    Article  PubMed  CAS  Google Scholar 

  7. Hsueh WA, Law RE. Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am J Med. 1998;105(Suppl 1A):4S-14S.

    Article  PubMed  CAS  Google Scholar 

  8. Davidson MB. Clinical implications of insulin resistance syndromes. Am J Med. 1995;99:420–426.

    Article  PubMed  CAS  Google Scholar 

  9. National Institutes of Health. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III).

  10. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952–957.

    Article  PubMed  CAS  Google Scholar 

  11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.

    Article  Google Scholar 

  12. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12:413–423.

    Article  PubMed  CAS  Google Scholar 

  13. Sunayama S, Watanabe Y, Ohmura H, et al. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis. 1999;146:187–193.

    Article  PubMed  CAS  Google Scholar 

  14. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. The Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226–1232.

    Article  PubMed  CAS  Google Scholar 

  15. Khan MA, St Peter JV, Xue JL. A prospective randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25:708–711.

    Article  PubMed  CAS  Google Scholar 

  16. Friedlander Y, Kidron M, Caslake M, Lamb T, McConnell M, Bar-On H. Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis. 2000;148:141–149.

    Article  PubMed  CAS  Google Scholar 

  17. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol: Modifications of low-density lipoprotein that Increase its atherogenicity. N Engl J Med. 1989;320:915–924.

    Article  PubMed  CAS  Google Scholar 

  18. Cominacini L, Garbin U, Pastorino AM, et al. Increased susceptibility of LDL cholesterol to in vitro oxidation in patients with insulin-dependent and non-insulin dependent diabetes mellitus. Diabetes Res. 1994;26:173–184.

    PubMed  CAS  Google Scholar 

  19. Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93:229–240.

    Article  PubMed  CAS  Google Scholar 

  20. yamasaki Y, Kawamori R, Wasada T, et al. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. Tohoku J Exp Med. 1997;183:173–183.

    Article  PubMed  CAS  Google Scholar 

  21. Rosenstock J, Raskin P. Hypertension in diabetes mellitus. Cardiol Clin. 1988;6:547–560.

    PubMed  CAS  Google Scholar 

  22. Scherbaum W, Burkhard G, for the German Pioglitazone Study Group. Pioglitazone reduces blood pressure in patients with type-2-diabetes mellitus [Abstract]. Diabetes. 2001;60 (Suppl 2):A462.

    Google Scholar 

  23. Bakst A, Schwartz S, Fischer JS, et al. Avandia worldwide awareness registry: Improved metabolic control with initiation of rosiglitazone in a diabetes clinic setting [Abstract]. Diabetes. 2001;50 (Suppl 2):A430.

    Google Scholar 

  24. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone, N Engl J Med. 1994;331:1188–1193.

    Article  PubMed  CAS  Google Scholar 

  25. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hyperten. 1995;8:316–320.

    Article  CAS  Google Scholar 

  26. Kawasaki J, Hirano K, Kanaide H, et al. Mechanisms of vasorelaxation induced by troglitazone: A novel antidiabetic drug, in the porcine coronary artery. Circulation. 1998;98:2446–2252.

    PubMed  CAS  Google Scholar 

  27. Song J, Walsh MF, Sowers JR, et al. Troglitazone reduces contraction by inhibition of vascular smooth muscle cell calcium currents and not endothelial nitric oxide production. Diabetes. 1997;6:659–664.

    Article  Google Scholar 

  28. Gaenzer H, Neumayr G, Marschang P, et al. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am J Cardiol. 2002;89:431–434.

    Article  PubMed  CAS  Google Scholar 

  29. Steinberg HO, Chaker H, Leaming R. Obesity/insulin resistance is associated with endothelial dysfunction: Implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601–2610.

    Article  PubMed  CAS  Google Scholar 

  30. Anand MM, Fonseca VA. Endothelial dysfunction and type 2 diabetes. Pract Diabetol. 1999;18:23–27.

    Google Scholar 

  31. Lehmann ED, Riley WA, Clarkson P, et al. Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lancet. 1997;350(Suppl 1):14–19.

    Article  Google Scholar 

  32. Avena R, Mitchell ME, Sidawy AN. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg. 1998;28:1024–1031.

    Article  PubMed  CAS  Google Scholar 

  33. Tack CJ, Ong MK, Lutterman JA, et al. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance: Effects of troglitazone. Diabetologia. 1998;41:569–576.

    Article  PubMed  CAS  Google Scholar 

  34. Murakami T, Mizuno S, Ohnaka M. Troglitazone restores endothelium-dependent vasomotion of resistance coronary artery [Abstract]. Circulation. 1998;98(Suppl):I-111A.

    Google Scholar 

  35. Mohanty P, Aljada A, Ghanim H, et al. Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduces P47phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotatic protein-1 (MCP-1): Evidence of a potent anti-inflammatory effect [Abstract]. Diabetes. 2001;50(Suppl 2):A68.

    Google Scholar 

  36. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420–1426.

    Article  PubMed  Google Scholar 

  37. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818–1820.

    Article  PubMed  CAS  Google Scholar 

  38. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452–3456.

    Article  PubMed  CAS  Google Scholar 

  39. Huber K, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease: Status report 2001. Thromb Res. 2001;103(Suppl 1):S7-S19.

    Article  PubMed  CAS  Google Scholar 

  40. Jokl R, Colwell JA. Arterial thrombosis and atherosclerosis in diabetes. Diabet Rev. 1997;5:316.

    Google Scholar 

  41. Melidonis A, Stefanidis A, Tournis S, et al. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. Clin Cardiol. 2000;23:160–164.

    Article  PubMed  CAS  Google Scholar 

  42. Sobel BE. Coronary artery disease and fibrinolysis: From the blood to the vessel wall. Thromb Haemost. 1999;82(Suppl):8–13.

    PubMed  Google Scholar 

  43. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2108–2116.

    Article  PubMed  CAS  Google Scholar 

  44. Fonseca VA, Reynolds T, Hemphil D, et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1998;12:181–186.

    Article  PubMed  CAS  Google Scholar 

  45. McTernan PG, Eggo MC, Smith SA, et al. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human subcutaneous adipocytes [Abstract]. Diabetes. 2001;50(Suppl 2):A275.

    Google Scholar 

  46. Fuell DL, Freed MI, Greenberg AS, et al. The effect of treatment with rosiglitazone on C-reactive protein and interleukin-6 in patients with type 2 diabetes [Abstract]. Diabetes. 2001;50 (Suppl 2):A435.

    Google Scholar 

  47. Mattock MB, Morrish NJ, Viberti GC, et al. Prospective study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes. 1992;41:736–741.

    Article  PubMed  CAS  Google Scholar 

  48. Solerte SB, Rondanelli M, Giacchero R, et al. Serum glucagons concentration and hyperinsulinaemia influence renal haemodynamics and urinary protein loss in normotensive patients with central obesity. Int J Obesity Relat Metabol Dis. 1999;23:997–1003.

    Article  CAS  Google Scholar 

  49. Fujii M, Takemura R, Yamaguchi M. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism. 1997;46:981–983.

    Article  PubMed  CAS  Google Scholar 

  50. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 1998;21:2135–2139.

    Article  PubMed  CAS  Google Scholar 

  51. Bakris G, Weston WM, Rappaport EB, et al. Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetes [Abstract]. Diabetologia. 1999;42(Suppl 1):230A.

    Google Scholar 

  52. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280–288.

    Article  PubMed  CAS  Google Scholar 

  53. Nakamura T, Ushiyama T, Shimada N, et al. Comparative effects of pioglitazone, glibencamide, and volgibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000;14:250–254.

    Article  PubMed  CAS  Google Scholar 

  54. de Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes. 2001;50:1863–71.

    Article  PubMed  Google Scholar 

  55. Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 1999;22:288–293.

    Article  PubMed  CAS  Google Scholar 

  56. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM) [Abstract]. Diabetes. 2000;49(Suppl 1):A299.

    Google Scholar 

  57. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 2001;104:1670–1675.

    PubMed  CAS  Google Scholar 

  58. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes. 1997;46:433–439.

    Article  PubMed  CAS  Google Scholar 

  59. Sutton MS, Dole JF, Rappaport EB. Rosiglitazone does not adversely affect cardiac structure of function in patients with type 2 diabetes [Abstract]. Diabetes 1999;49(Suppl):A102.

    Google Scholar 

  60. Rubin CJ, Shaffer S, Pioglitazone 001 Study Group. Echocar-diographic assessment in patients with type 2 diabetes mellitus treated with pioglitazone [Abstract]. Diabetes. 2000;49(Suppl):A364.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tulane Diabetes Program, Department of Medicine, Section of Endocrinology, Tulane University Medical Center, SL-53, 1430 Tulane Avenue, 70112-2699, New Orleans, LA, USA

    Biswanath P. Gouda MBBS, Sunil Asnani MD & Vivian A. Fonseca MD (Professor of Medicine)

Authors
  1. Biswanath P. Gouda MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sunil Asnani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vivian A. Fonseca MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article.

About this article

Cite this article

Gouda, B.P., Asnani, S. & Fonseca, V.A. Effects of thiazolidinediones on cardiovascular risk factors. Compr Ther 28, 200–206 (2002). https://doi.org/10.1007/s12019-002-0018-8

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12019-002-0018-8

Keywords

Search

Navigation